Normal
0

false
false
false

EN-IN
X-NONE
HI

MicrosoftInternetExplorer4

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
mso-bidi-font-size:10.0pt;
font-family:”Calibri”,”sans-serif”;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:”Times New Roman”;
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;}
table.MsoTableGrid
{mso-style-name:”Table Grid”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-priority:59;
mso-style-unhide:no;
border:solid black 1.0pt;
mso-border-themecolor:text1;
mso-border-alt:solid black .5pt;
mso-border-themecolor:text1;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-border-insideh:.5pt solid black;
mso-border-insideh-themecolor:text1;
mso-border-insidev:.5pt solid black;
mso-border-insidev-themecolor:text1;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,”sans-serif”;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;
mso-bidi-language:AR-SA;}

thyorcae arogayam

Thyrocare has  come out with its maiden results on 11/6/2016 . The company has also declared final dividend of 25% thus making the total dividend payout as 100% (Rs. 10/-). The results are ok but not phenomenal. Along with Dr. Lal Path Labs Thyrocare Technologies  Ltd. is the only listed company in organized diagnostics space.

Though full details are yet not available, the company seems to be cruising well. It has posted a decent 31% top line growth and PBT growth of 21%.  Thus profits seem to growing but albeit at a little slower pace than the revenues. The PAT was grown by 17.7% on account of increased taxation. The company is cash rich and has incurred zero financial charges. Thyrocare has pioneered a unique model of single computerized Lab & collection of samples at door step.

Thyrocare Results                                                                                       all figures in Rs. Million

 

Q4  fy2016

Annual fye 2016

Annual fye 2015

Total Income

651

2410

1829

PBT

218

818

678

PAT

139

518

440

Equity

537

537

505

EPS

2.71

10.06

9.14

 

Thyrocare vs Dr.Lal PathLabs                                                               (all figures in Rs. Million)

 

Thyrocare ( fye 2016)

Dr. Lal Path Labs (fye 2016)

Total Income

2410

7858

PBT

818

1918

PAT

518

1258

Equity

537

827

EPS

10.06

15.31

Dividend

100%

24.2%

Market Price (10/6/16)

604

988

PE ratio

60

64.5

Net Profit Margin

21.5

16

Advertisements